Oppenheimer reiterates an Outperform rating on Ideaya Biosciences (IDYA) with a $40 price target after the company announced that it met with ...

Oppenheimer downgraded Arvinas (ARVN ... of investors polled in a recent survey said they wanted to see the trial hit on the Intention-to-Treat endpoint and argues that without an ITT win it ...

added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to Outperform from Perform, citing a favorable valuation setup ahead of a mid-stage trial readout for its eczema ...

Oppenheimer analyst Matthew Biegler says Olema Oncology (OLMA) published a revised corporate deck today which included an ...